PROTAGONIST THERAPEUTICS, INC.

(PTGX)
  Report
Delayed Nasdaq  -  04:00 2022-06-24 pm EDT
9.080 USD   -2.37%
06/02PROTAGONIST THERAPEUTICS, INC : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/01Protagonist Therapeutics to Participate at the Jefferies Healthcare Conference
PR
05/26Protagonist Therapeutics, Inc. to Present Updated Phase 2 Rusfertide Clinical Results in Polycythemia Vera (PV) at ASCO 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Protagonist Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022

05/04/2022 | 05:19pm EDT

Protagonist Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was USD 20.93 million compared to USD 24 million a year ago. Basic loss per share from continuing operations was USD 0.43 compared to USD 0.54 a year ago.


© S&P Capital IQ 2022
All news about PROTAGONIST THERAPEUTICS, INC.
06/02PROTAGONIST THERAPEUTICS, INC : Submission of Matters to a Vote of Security Holders (form ..
AQ
06/01Protagonist Therapeutics to Participate at the Jefferies Healthcare Conference
PR
05/26Protagonist Therapeutics, Inc. to Present Updated Phase 2 Rusfertide Clinical Results i..
CI
05/18Piper Sandler Adjusts Price Target on Protagonist Therapeutics to $35 From $60, Reitera..
MT
05/05PROTAGONIST THERAPEUTICS, INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
AQ
05/05SVB Leerink Adjusts Protagonist Therapeutics' Price Target to $30 from $50, Keeps Outpe..
MT
05/04PROTAGONIST THERAPEUTICS : Q1 Earnings Snapshot
AQ
05/04Protagonist Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended Mar..
CI
04/26Protagonist Therapeutics' Shares Plummet After Reporting Trial Data for Inflammatory Bo..
MT
04/26Top Midday Decliners
MT
More news
Analyst Recommendations on PROTAGONIST THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 31,9 M - -
Net income 2022 -157 M - -
Net cash 2022 174 M - -
P/E ratio 2022 -2,87x
Yield 2022 -
Capitalization 442 M 442 M -
EV / Sales 2022 8,39x
EV / Sales 2023 33,3x
Nbr of Employees 122
Free-Float 98,6%
Chart PROTAGONIST THERAPEUTICS, INC.
Duration : Period :
Protagonist Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROTAGONIST THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 9,08 $
Average target price 40,00 $
Spread / Average Target 341%
EPS Revisions
Managers and Directors
Dinesh V. Patel President, Chief Executive Officer & Director
Asif Ali Chief Financial Officer & Executive Vice President
Harold E. Selick Chairman
Mark L. Smythe Vice President-Technology
David Y. Liu Chief Research & Development Strategy Officer
Sector and Competitors
1st jan.Capi. (M$)
PROTAGONIST THERAPEUTICS, INC.-73.45%442
MODERNA, INC.-43.20%57 385
IQVIA HOLDINGS INC.-24.22%40 468
LONZA GROUP AG-32.67%39 851
SEAGEN INC.16.00%33 010
CELLTRION, INC.-13.38%18 371